Alpha-2C Antagonists for Sleep Apnea Airway Patency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sleep-related breathing disorders such as obstructive sleep apnea (OSA) are inadequate, with up to 50% of patients not tolerating continuous positive airway pressure (CPAP) in the long term, highlighting the need for effective therapeutic agents.
Innovation Solution
The use of 3-substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)azacycles as alpha-2C adrenoceptor antagonists, which inhibit upper airway collapsibility and are suitable for treating obstructive and central sleep apneas and snoring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If continuous positive airway pressure (CPAP) is used to treat sleep apnea, then airway patency is maintained, but patient tolerance and long-term compliance deteriorate (up to 50% of patients do not tolerate it long term)
Solution Approach 1:
The patent replaces the mechanical CPAP system with a pharmacological solution - alpha-2C adrenoceptor antagonist compounds that directly作用于 the neural control of upper airway muscles. This substitution eliminates the need for external mechanical pressure devices and improves patient compliance while maintaining airway patency through endogenous muscle tone regulation.
Solution Approach 2:
The invention enables the body's own neuromuscular system to maintain airway patency through pharmacological modulation of alpha-2C adrenoceptors. The compounds enhance the natural reflex control of upper airway dilator muscles, allowing the respiratory system to self-regulate airway openness without external mechanical support, thereby improving long-term compliance.
2Reliability
If alpha-2C adrenoceptor antagonists are used to increase hypoglossal motoneuron excitability, then upper airway stability is improved, but the mechanism complexity increases
Solution Approach 1:
The patent utilizes parameter changes at the molecular level - specifically, the binding affinity and selectivity of alpha-2C adrenoceptor antagonist compounds. By optimizing the pharmacological parameters of these compounds (such as their selective antagonism of alpha-2C versus other adrenoceptor subtypes), the invention achieves reliable upper airway stabilization through a well-defined molecular mechanism rather than complex systemic effects.
3Reliability
If noradrenergic drive is increased to counteract sleep-dependent decline of hypoglossal motoneuron excitability, then genioglossus muscle activity is maintained, but side effects may increase
Solution Approach 1:
The patent applies local quality through selective receptor subtype antagonism. The alpha-2C adrenoceptor antagonist compounds specifically target alpha-2C receptors in the brainstem regions controlling hypoglossal motoneurons, while minimizing effects on other adrenoceptor subtypes. This selective action maintains genioglossus muscle activity during sleep without triggering the broad sympathetic effects and side effects associated with non-selective noradrenergic stimulation.
Data Source
AI summary
The present invention relates to α2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular 3-substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)azacycles of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.